tradingkey.logo

碧迪医疗

BDX
200.090USD
-0.800-0.40%
收盘 12/15, 16:00美东报价延迟15分钟
57.11B总市值
34.30市盈率 TTM

碧迪医疗

200.090
-0.800-0.40%

关于 碧迪医疗 公司

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

碧迪医疗简介

公司代码BDX
公司名称Becton Dickinson and Co
上市日期Oct 31, 2099
CEOPolen (Thomas E)
员工数量72000
证券类型Ordinary Share
年结日Oct 31
公司地址One Becton Drive
城市FRANKLIN LAKES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编07417-1880
电话12018476800
网址https://www.bd.com/
公司代码BDX
上市日期Oct 31, 2099
CEOPolen (Thomas E)

碧迪医疗公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Mr. Gregory J. Hayes
Mr. Gregory J. Hayes
Independent Director
Independent Director
6.05K
+659.55%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
其他
1.88B
34.09%
地区USD
名称
营收
占比
United States
3.18B
57.72%
International
2.33B
42.26%
业务
地区
业务USD
名称
营收
占比
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
其他
1.88B
34.09%

股东统计

更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
其他
69.45%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
其他
69.45%
股东类型
持股股东
占比
Investment Advisor
48.66%
Investment Advisor/Hedge Fund
35.74%
Research Firm
2.91%
Pension Fund
2.39%
Bank and Trust
1.46%
Hedge Fund
1.42%
Sovereign Wealth Fund
1.36%
Individual Investor
0.60%
Insurance Company
0.32%
其他
5.13%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
2786
268.89M
98.17%
+69.96K
2025Q3
2887
268.83M
99.00%
+3.34M
2025Q2
2905
265.92M
96.81%
+120.40K
2025Q1
2872
266.25M
96.81%
-11.23M
2024Q4
2862
265.61M
95.72%
+1.13M
2024Q3
2775
265.14M
93.34%
+4.39M
2024Q2
2770
259.79M
92.17%
+1.30M
2024Q1
2779
258.85M
91.59%
-5.84M
2023Q4
2763
257.96M
92.19%
-5.24M
2023Q3
2735
263.83M
91.15%
+1.97M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
32.17M
11.22%
+4.30M
+15.41%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.18M
5.64%
+3.60M
+28.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.15M
5.29%
+360.45K
+2.44%
Jun 30, 2025
State Street Investment Management (US)
13.41M
4.68%
-579.46K
-4.14%
Jun 30, 2025
First Eagle Investment Management, L.L.C.
8.79M
3.07%
+3.27M
+59.18%
Jun 30, 2025
MFS Investment Management
7.69M
2.68%
+1.58M
+25.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.35%
+244.20K
+3.77%
Jun 30, 2025
ClearBridge Investments, LLC
3.80M
1.33%
+321.67K
+9.24%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares U.S. Medical Devices ETF
4.25%
FPA Global Equity ETF
3.12%
Cullen Enhanced Equity Income ETF
3.1%
American Century Focused Large Cap Value ETF
3.04%
iShares Large Cap Value Active ETF
2.72%
First Eagle Global Equity ETF
2.66%
Franklin ClearBridge Enhanced Income ETF
2.66%
T Rowe Price Capital Appreciation Equity ETF
2.65%
Brandes US Value ETF
2.26%
First Trust Indxx Medical Devices ETF
1.92%
查看更多
iShares U.S. Medical Devices ETF
占比4.25%
FPA Global Equity ETF
占比3.12%
Cullen Enhanced Equity Income ETF
占比3.1%
American Century Focused Large Cap Value ETF
占比3.04%
iShares Large Cap Value Active ETF
占比2.72%
First Eagle Global Equity ETF
占比2.66%
Franklin ClearBridge Enhanced Income ETF
占比2.66%
T Rowe Price Capital Appreciation Equity ETF
占比2.65%
Brandes US Value ETF
占比2.26%
First Trust Indxx Medical Devices ETF
占比1.92%

分红派息

近5年累计派现 5.54B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Nov 06, 2025
BDX.NB Final Cash Dividend of gross USD 1.05 paid on Dec 31, 2025 going ex on Dec 08, 2025
Dec 08, 2025
Dec 31, 2025
Dec 08, 2025
Jul 22, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Sep 30, 2025 going ex on Sep 08, 2025
Sep 08, 2025
Sep 30, 2025
Sep 08, 2025
Apr 29, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Jun 30, 2025 going ex on Jun 09, 2025
Jun 09, 2025
Jun 30, 2025
Jun 09, 2025
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
查看更多

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

碧迪医疗的前五大股东是谁?

碧迪医疗 的前五大股东如下:
The Vanguard Group, Inc.持有股份:32.17M,占总股份比例:11.22%。
T. Rowe Price Investment Management, Inc.持有股份:16.18M,占总股份比例:5.64%。
BlackRock Institutional Trust Company, N.A.持有股份:15.15M,占总股份比例:5.29%。
State Street Investment Management (US)持有股份:13.41M,占总股份比例:4.68%。
First Eagle Investment Management, L.L.C.持有股份:8.79M,占总股份比例:3.07%。

碧迪医疗的前三大股东类型是什么?

碧迪医疗 的前三大股东类型分别是:
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.

有多少机构持有碧迪医疗(BDX)的股份?

截至2025Q4,共有2786家机构持有碧迪医疗的股份,合计持有的股份价值约为268.89M,占公司总股份的98.17%。与2025Q3相比,机构持股有所增加,增幅为-0.83%。

哪个业务部门对碧迪医疗的收入贡献最大?

在FY2025Q3,Medication Delivery Solutions业务部门对碧迪医疗的收入贡献最大,创收1.13B,占总收入的20.55%。
KeyAI